Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women - The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study

Next Previous
Search
Trial Profile

Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women - The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Anal cancer; Cervical cancer; Cervical intraepithelial neoplasia; Condylomata acuminata; Gynaecological cancer; Human papillomavirus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Acronyms FUTURE III
  • Sponsors Merck & Co; Merck Sharp & Dohme

    • Most Recent Events

    • 18 Feb 2010 New end-of-study per protocol efficacy analysis presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN 2010) conference, according to a Merck and Co media release.
    • 31 Aug 2009 Interim results were published in the Journal of Clinical Outcomes Management.
    • 14 Jul 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top